Concord Biotech Ltd reports Q2FY27 revenue of ₹309.1 crore, up 25.1% YoY, with EBITDA margin at 33.8%
- Consolidated EBITDA was ₹104.4 crore; net profit rose 10.3% YoY to ₹69.6 crore.
- EBITDA margin declined from 35.8% a year earlier, with higher input costs and product mix cited as factors.
- Updates: launched the Inspira dermatology division, received two ANDA approvals, completed a USFDA inspection with one minor procedural observation unrelated to GMP, and approved a 1:1 bonus issue.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=118d1eac-e193-46cb-ae1b-a1caa31993e0.pdf